Liver and biliary tract cancer trials in France

In France 107 Also abroad 1314

107 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Not yet taking people in France
A Phase 2 Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
Where
Bordeaux, Dijon, Lyon, Villejuif
Age
18 years and over
People
14 worldwide
Run by
Elevar Therapeutics Inc.
See details and how to join2025-523923-22-00 · EU 2025-523923-22-00
Phase 1/2Taking people
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Where
Lyon, Marseille, Paris
Age
18 years and over
People
616 worldwide
Run by
Verastem, Inc.
See details and how to joinNCT07020221
Phase 2Taking people
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
Where
Grenoble Cedex 9, Montpellier Cedex 5, Nantes, Pessac, Poitiers, Villejuif
Age
18 years to 100 years
People
104 worldwide
Run by
CatalYm GmbH
See details and how to joinNCT07219459 · EU 2025-520675-86-00
No phaseTaking people
Effect of Acute Endurance Exercise on the Production of FGF21 and Follistatin in Patients With Hepatocellular Carcinoma
Where
Clermont-Ferrand
Age
18 years to 80 years
People
12
Run by
University Hospital, Clermont-Ferrand
See details and how to joinNCT07189624
Phase 2Taking people
A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
Where
Bordeaux, Dijon, Lyon, Paris
Age
18 years and over
People
30 worldwide
Run by
Elevar Therapeutics
See details and how to joinNCT07359820
Phase 2Taking people
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Bordeaux, Brest, Lille, Montpellier, Pierre-Bénite, Villejuif
Age
18 years and over
People
111 worldwide
Run by
Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00
Phase 2Taking people
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Where
Angers, Dijon, Lyon, Marseille, Paris, Poitiers, Saint-Herblain Cedex
Age
18 years and over
People
750 worldwide
Run by
DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00
No phaseTaking people
Observational Study Protocol: LIVER-R
Where
Avignon, Boulogne-sur-Mer, Grenoble, Marseille, Mulhouse, Paris, Poitiers, St-Malo, Strasbourg
Age
18 years to 130 years
People
4,000 worldwide
Run by
AstraZeneca
See details and how to joinNCT06252753
Phase 3Taking people
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Where
Brest, Clermont-Ferrand, Clichy, Creteil, Montpellier Cedex 5, Pessac, Poitiers, Saint-Herblain, Toulouse Cedex 9, Villejuif
Age
18 years and over
People
286 worldwide
Run by
Jazz Pharmaceuticals
See details and how to joinNCT06282575 · EU 2023-508219-21-00
Phase 1Taking people
Neoadjuvant Hypofractionated Stereotactic Body Radiation Therapy Prior to Surgery for Hepatocellular Carcinoma: a Feasibility Study.
Where
Lille
Age
18 years to 70 years
People
30
Run by
University Hospital, Lille
See details and how to joinNCT04587739
Phase 1/2Taking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Besancon Cedex, Bordeaux, Bordeaux Cedex, Dijon, Lyon, Montpellier Cedex 5, Paris, Rennes Cedex, Saint-Herblain Cedex, Toulouse Cedex 9, Villejuif
Age
18 years and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
Phase 2Taking people
Selective Internal Radiation Therapy and Capecitabine (Chemotherapy) Treatment for Liver Cancer
Where
Aurillac Cedex, Clichy, Montpellier Cedex 5, Nantes, Pessac, Poitiers, Rennes Cedex, Villejuif
Age
18 years and over
People
62
Run by
Center Eugene Marquis
See details and how to joinNCT05265208 · EU 2024-516683-29-00
Phase 1/2Taking people
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Where
Bobigny Cedex, Grenoble Cedex 9, Montpellier Cedex 5, Pessac, Saint-Priest-en-Jarez
Age
18 years and over
People
198 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07291076 · EU 2025-523602-33-00
No phaseTaking people
"Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases".
Where
Strasbourg
Age
18 years and over
People
800
Run by
Institut National de la Santé Et de la Recherche Médicale, France
See details and how to joinNCT04690972
No phaseTaking people
Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers
Where
Lille
Age
18 years and over
People
360
Run by
University Hospital, Lille
See details and how to joinNCT06958224
Phase 1Taking people
A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer
Where
Bron, Montpellier Cedex 5, Nantes, Vandoeuvre Les Nancy Cedex, Villejuif
Age
18 years and over
People
148 worldwide
Run by
Bayer
See details and how to joinNCT06764316 · EU 2024-516615-25-00
No phaseTaking people
Variability of Microwave Ablation Volume Based on Clinical, Radiological, Biological, and Tissue Factors
Where
Vandœuvre-lès-Nancy
Age
18 years to 100 years
People
90
Run by
Central Hospital, Nancy, France
See details and how to joinNCT07413640
Phase 2Taking people
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
Where
Paris, Villejuif
Age
18 years and over
People
90 worldwide
Run by
Delcath Systems Inc.
See details and how to joinNCT06875128 · EU 2025-521966-91-00
Phase 3Taking people
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
Where
Brest, Clichy, Dijon, Lille Cedex, Lyon, Marseille, Montpellier Cedex 5, Pessac, Villejuif Cedex
Age
18 years to 99 years
People
620 worldwide
Run by
AstraZeneca
See details and how to joinNCT06467357 · EU 2023-508057-19-00
Phase 3Taking people
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Where
Clichy, Lille, Lyon Cedex 04, Montpellier Cedex 5, Nantes, Nice, Pessac, Rennes Cedex, Toulouse Cedex 9
Age
18 years and over
People
1,220 worldwide
Run by
AstraZeneca
See details and how to joinNCT06921785 · EU 2024-518210-81-00
No phaseTaking people
Oncology, Undernutrition and Sensoriality: Links, Mechanisms and Levers for Action
Where
Dijon
Age
18 years and over
People
306
Run by
Centre Hospitalier Universitaire Dijon
See details and how to joinNCT06600295
Phase 1/2Taking people
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
Where
Dijon, Lyon Cedex 04, Rennes Cedex, Villejuif
Age
18 years and over
People
138 worldwide
Run by
Pfizer
See details and how to joinNCT07227012 · EU 2025-523525-17-00
Phase 1/2Taking people
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Where
Bordeaux, Clermont-Ferrand, Lyon, Nîmes, Saint-Herblain, Strasbourg, Toulouse, Vandœuvre-lès-Nancy, Villejuif
Age
12 years and over
People
300 worldwide
Run by
PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750
Phase 3Taking people
A clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043)
Where
Angers, Limoges Cedex I, Strasbourg Cedex 2, Toulouse Cedex 9, Villejuif
Age
18 years and over
People
134 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to join2025-524160-38-00 · EU 2025-524160-38-00
Phase 1Taking people
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Where
Besancon Cedex, Bordeaux, Caen Cedex 5, Clermont Ferrand Cedex1, Marseille, Nice Cedex 2, Paris, Rennes Cedex, Saint-Herblain, Strasbourg Cedex 2, Vandoeuvre Les Nancy_ Cedex, Villejuif
Age
18 years and over
People
1,394 worldwide
Run by
Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00